abrdn Healthcare Investors (NYSE:HQH) Sets New 52-Week High – Here’s What Happened

abrdn Healthcare Investors (NYSE:HQH)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $20.30 and last traded at $20.05, with a volume of 431484 shares. The stock had previously closed at $19.89.

abrdn Healthcare Investors Price Performance

The company’s fifty day moving average is $19.25 and its 200 day moving average is $18.36.

abrdn Healthcare Investors Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, February 20th will be given a dividend of $0.63 per share. This is a positive change from abrdn Healthcare Investors’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Friday, February 20th. This represents a $2.52 dividend on an annualized basis and a yield of 12.8%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HQH. Eastern Bank acquired a new position in shares of abrdn Healthcare Investors in the 3rd quarter valued at approximately $30,000. Newbridge Financial Services Group Inc. bought a new stake in shares of abrdn Healthcare Investors in the second quarter worth $34,000. Guerra Advisors Inc acquired a new stake in abrdn Healthcare Investors in the third quarter valued at $39,000. Geneos Wealth Management Inc. boosted its stake in abrdn Healthcare Investors by 9,232.3% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock valued at $45,000 after acquiring an additional 2,862 shares during the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new position in abrdn Healthcare Investors during the 4th quarter worth $48,000. Institutional investors and hedge funds own 32.60% of the company’s stock.

abrdn Healthcare Investors Company Profile

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.